Open Label Extension In Cancer Patients
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | October 2009 |
| End Date: | June 2013 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone
metastases who participated in the double-blind Study A4091003 and who wish to receive
open-label therapy.
Inclusion Criteria:
- Prostate cancer, breast cancer, renal cell carcinoma or multiple myeloma that has
been diagnosed as having metastasized to bone;
- Karnofsky Performance Score ≥40% at Baseline;
- patients randomized and treated with intravenous study drug in double-blind Study
A4091003.
Exclusion Criteria:
- Patient was withdrawn from Study A4091003 for an adverse event or serious adverse
event;
- Occurrence of any adverse event or condition during Study A4091003 or since
termination from that study that, in the opinion of the Investigator, would put the
patient at increased safety risk or should exclude the subject from participating in
the open-label extension Study A4091029.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials